Literature DB >> 6108750

Changes in prevalence, severity, and recovery in tardive dyskinesia with age.

J M Smith, R J Baldessarini.   

Abstract

Advancing age is one of the few factors suggested to predict increased risk of tardive dyskinesias (TDs). By pooling and reanalyzing available epidemiological data, we found strong linear correlations between ages (< 40 to 70 years) and both the prevalences and severity of TD, while neither increased significantly after age 70 years. There was also a strong inverse correlation between rates of spontaneous remission of TD and age (< 30 to > 80 years); TD in those younger than 60 years improved over three times as often as in older patients. These correlations are not readily explained by the duration of previous exposure to neuroleptic drugs and may reflect increased sensitivity of the aging brain to them. These observations support caution in the prolonged use of neuroleptics in patients older than age 50 years but encourage optimism for eventual spontaneous remission of TD in young adults.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6108750     DOI: 10.1001/archpsyc.1980.01780250054006

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  46 in total

1.  Tardive Dyskinesia.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

Review 2.  Adverse effects of antidepressants in the elderly.

Authors:  L Nolan; K O'Malley
Journal:  Drugs Aging       Date:  1992 Sep-Oct       Impact factor: 3.923

3.  Ethical and Policy Considerations in the Application of Pharmacogenomic Testing for Tardive Dyskinesia: Case Study of the Dopamine D3 Receptor.

Authors:  Michel C F Shamy; Clement Zai; Vincenzo S Basile; James L Kennedy; Daniel J Müller; Mario Masellis
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-06-01

4.  Analysis of genetic variations in the dopamine D1 receptor (DRD1) gene and antipsychotics-induced tardive dyskinesia in schizophrenia.

Authors:  I-Ching Lai; Geng-Han Mo; Mao-Liang Chen; Ying-Chieh Wang; Jen-Yeu Chen; Ding-Lieh Liao; Ya-Mei Bai; Chao-Cheng Lin; Tzu-Ting Chen; Ying-Jay Liou
Journal:  Eur J Clin Pharmacol       Date:  2010-12-22       Impact factor: 2.953

5.  The management of neuroleptic-induced CNS effects.

Authors:  B F Hoffman; M V Seeman
Journal:  Can Fam Physician       Date:  1981-10       Impact factor: 3.275

6.  Tardive dyskinesia associated with metoclopramide.

Authors:  B E Wiholm; O Mortimer; G Boethius; J E Häggström
Journal:  Br Med J (Clin Res Ed)       Date:  1984-02-18

7.  Levodopa and receptor sensitivity modification in tardive dyskinesia.

Authors:  D E Casey; J Gerlach; N Bjørndal
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

8.  Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate.

Authors:  T M Hyde; M F Egan; L L Wing; R J Wyatt; D R Weinberger; J E Kleinman
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

Review 9.  Current Methods for the Treatment and Prevention of Drug-Induced Parkinsonism and Tardive Dyskinesia in the Elderly.

Authors:  Carlos Estevez-Fraga; Paul Zeun; Jose Luis López-Sendón Moreno
Journal:  Drugs Aging       Date:  2018-11       Impact factor: 3.923

Review 10.  Drug treatment of resistant schizophrenia. Limitations and recommendations.

Authors:  A E Farmer; A Blewett
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.